PEG300  (Synonyms: Polyethylene glycol 300)

PEG300 (Polyethylene glycol 300), a neutral polymer of molecular weight 300, is a water-soluble, low immunogenic and biocompatible polymer formed by repeating units of ethylene glycol^[1][2].

The FDA has approved polyethylene glycol (PEG) for use as a vehicle or base in foods, cosmetics and pharmaceuticals, including injectable, topical, rectal and nasal formulations. PEG shows little toxicity, and is eliminated from the body intact by either the kidneys (for PEGs < 30 kDa) or in the faeces (for PEGs > 20 kDa). PEG lacks immunogenicity, and antibodies to PEG are generated in rabbits only if PEG is combined with highly immunogenic proteins^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
The final concentration of PEG300 can go up to 50% in the formulations for intravenous and intramuscular injection without any toxic effects. When administered orally, the highest concentration of PEG300 can reach up to 90%^[4][5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

300.00

Liquid

25322-68-3

[H]OCCO[H].[n]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

• [1]. J.Billingham, et al. Adsorption of polyamine, polyacrylic acid and polyethylene glycol on montmorillonite: An in situ study using ATR-FTIR. Volume 14, Issue 1, March 1997, Pages 19-34.

  [2]. Lee CC, et al. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci. 2020 Jan 7;27(1):12.  [Content Brief]

  [3]. Harris JM, et al. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003 Mar;2(3):214-21.  [Content Brief]

  [4]. Xiaoqin Wang, et al. Injectable silk-polyethylene glycol hydrogels. Acta Biomater. 2015 Jan;12:51-61.  [Content Brief]

  [5]. Ellen Weisberg, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.  [Content Brief]